FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 197 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide August 9, 2024 A Safer, Better Treatment Option for Some Younger Women with Breast... January 11, 2023 PICOS Score May Help in Identification of Patients with Brain Metastasis... June 24, 2020 Cómo mi diagnóstico de cáncer a los 17 años cambió mi... December 14, 2020 Load more HOT NEWS News digest – ovarian cancer blood test, statins, spending review and... Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... Air Pollution and Breast Cancer Risk – A Link That Calls...
